XML 33 R17.htm IDEA: XBRL DOCUMENT
v3.25.1

Note 8 - Other Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2024
Notes to Financial Statements |
Intangible Assets Disclosure [Text Block] | NOTE 8. OTHER INTANGIBLE ASSETS The following roll-forward presents the Company’s other intangible assets as of December 31, 2023 (in thousands):
|  | Balance at December 31, 2023 |
|  |  |  |  |  | Accumulated |  |  | Impairments |  |  |  |  |
|  | Gross |  |  | Amortization |  |  | to Date |  |  | Net |
Indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
DERMAdoctor Trade names |  | $ | 2,080 |  |  | $ | — |  |  | $ | (2,080 | ) |  | $ | — |
Amortizable intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
DERMAdoctor Customer relationships |  |  | 290 |  |  |  | (60 | ) |  |  | (230 | ) |  |  | — |
DERMAdoctor Trade secrets / product formulations |  |  | 2,890 |  |  |  | (515 | ) |  |  | (2,375 | ) |  |  | — |
Total other intangible assets |  | $ | 5,260 |  |  | $ | (575 | ) |  | $ | (4,685 | ) |  | $ | — |
The Company determined that its indefinite-lived and long-lived amortizable intangible assets related to its DERMAdoctor business were fully impaired during the year ended December 31, 2023. As such, the Company recorded an intangible asset impairment charge of $2.1 million in the year ended December 31, 2023 which is included in net loss from discontinued operations in the Company’s consolidated statements of operations. There was no such intangible asset impairment charge recorded during the year ended December 31, 2024. The impairment information is discussed in Note 2, “Summary of Significant Accounting Policies.” On March 25, 2024, we closed the DERMAdoctor Divestiture, resulting in the sale of the indefinite-lived and long-lived amortizable intangible assets. See additional information in Note 21, “DERMAdoctor Divestiture and Discontinued Operations.” Amortization expense was $152 thousand during the year ended December 31, 2023 which is included in net loss from discontinued operations. There was no such expense recorded during the year ended December 31, 2024 as the related assets were fully impaired prior to 2024 and subsequently sold in conjunction with the DERMAdoctor Divestiture.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration